IP Library › Granted Patent US 12,383,532
Granted Patent B2
US 12,383,532 · App. 17/948,542 · Granted Aug 12, 2025

Compositions and methods comprising a combination of serotonergic drugs

Inventor: Andrew R. Chadeayne (Issaquah, WA)
Assignee: CAAMTECH, INC.
A61K31/4045A61K31/36A61K31/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,532
App. No.
17/948,542
Granted
Aug 12, 2025
Kind
B2
Abstract

This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

Claims (23)

1. A dosage formulation for treating a psychological disorder comprising a homogenous mixture of:

a first purified psilocybin derivative selected from the group consisting of [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, and salts thereof; and

a second purified psilocybin derivative selected from the group consisting of [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N-dimethyltryptamine, [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N-methyltryptamine, [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxytryptamine, [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate, 4-hydroxy-N,N,N-trimethyltryptamine, and salts thereof;

wherein the first purified psilocybin derivative is different than the second purified psilocybin derivative.

2. The dosage formulation of claim 1 , wherein the dosage formulation comprises a molar ratio between about 10:1 to about 1:10 of the first purified psilocybin derivative to the second purified psilocybin derivative.

3. The dosage formulation of claim 1 , wherein the dosage formulation comprises a molar ratio between about 100:1 to about 1:100 of the first purified psilocybin derivative to the second purified psilocybin derivative.

4. The dosage formulation of claim 1 , wherein the dosage formulation comprises a molar ratio between about 1,000:1 to about 1:1,000 of the first purified psilocybin derivative to the second purified psilocybin derivative.

5. The dosage formulation of claim 1 , wherein the dosage formulation comprises a molar ratio of about 10,000:1 to about 1:10,000 of the first purified psilocybin derivative to the second purified psilocybin derivative.

6. The dosage formulation of claim 1 , wherein the dosage formulation further comprises an excipient.

7. The dosage formulation of claim 6 , wherein the excipient is a stabilizer.

8. The dosage formulation of claim 7 , wherein the stabilizer is an antioxidant.

9. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is [3-(2-dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

10. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 4-hydroxy-N,N-dimethyltryptamine.

11. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is [3-(2-methylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

12. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 4-hydroxy-N-methyltryptamine.

13. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is [3-(aminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

14. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 4-hydroxytryptamine.

15. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is [3-(2-trimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate.

16. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 4-hydroxy-N,N,N-trimethyltryptamine.

17. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 80-100% pure.

18. The dosage formulation of claim 1 , wherein the first purified psilocybin derivative is 90-100% pure.

19. The dosage formulation of claim 1 , wherein the second purified psilocybin derivative is 80-100% pure.

20. The dosage formulation of claim 1 , wherein the second purified psilocybin derivative is 90-100% pure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2022
From: CHADEAYNE, ANDREW R.
To: CAAMTECH, LLC
Reel/Frame 061152/0220 →
CHANGE OF NAME Recorded Sep 20, 2022
From: CAAMTECH, LLC
To: CAAMTECH, INC.
Reel/Frame 061481/0958 →
Continuity (17)
Continuation 17388252 · Jul 29, 2021
Continuation 17095430 · Nov 11, 2020
Continuation In Part 15893562 · Feb 9, 2018
Provisional Application 62457123 · Feb 9, 2017
Provisional Application 62587395 · Nov 16, 2017
Provisional Application 62587410 · Nov 16, 2017
Provisional Application 62587419 · Nov 16, 2017
Provisional Application 62587431 · Nov 16, 2017
Provisional Application 62592307 · Nov 29, 2017
Provisional Application 62592320 · Nov 29, 2017
Provisional Application 62593021 · Nov 30, 2017
Provisional Application 62595321 · Dec 6, 2017
Provisional Application 62595336 · Dec 6, 2017
Provisional Application 62598767 · Dec 14, 2017
Provisional Application 62609115 · Dec 21, 2017
Provisional Application 62613360 · Jan 3, 2018
Related Publication 20230029139A1 · Jan 26, 2023
References Cited (102)
US 3192111A · Hofmann et al. · 1965 [cited by applicant]
US 6303181B1 · Terranova et al. · 2001 [cited by applicant]
US 6306181B1 · Terranova et al. · 2001 [cited by applicant]
US 8859579B2 · Sewell · 2014 [cited by applicant]
US 10933073B2 · Chadeayne · 2021 [cited by applicant]
US 11753375B2 · Chadeayne · 2023 [cited by applicant]
US 11819475B2 · Chadeayne · 2023 [cited by applicant]
US 12006290B2 · Chadeayne · 2024 [cited by applicant]
US 20040034106A1 · Read et al. · 2004 [cited by applicant]
US 20050137255A1 · Petersen et al. · 2005 [cited by applicant]
US 20080293695A1 · Bristol et al. · 2008 [cited by applicant]
US 20110038958A1 · Kikuchi et al. · 2011 [cited by applicant]
US 20140243405A1 · Whalley et al. · 2014 [cited by applicant]
US 20150320814A1 · Patel et al. · 2015 [cited by applicant]
US 20160158298A1 · Kolsky · 2016 [cited by applicant]
US 20160250270A1 · Wendschuh et al. · 2016 [cited by applicant]
US 20160279073A1 · Donsky et al. · 2016 [cited by applicant]
US 20180021326A1 · Stamets · 2018 [cited by applicant]
US 20190105313A1 · Stamets · 2019 [cited by applicant]
US 20190142851A1 · Chadeayne · 2019 [cited by applicant]
US 20190192498A1 · Stamets · 2019 [cited by applicant]
US 20190350949A1 · Kucuksen et al. · 2019 [cited by applicant]
US 20200375967A1 · Stamets · 2020 [cited by applicant]
US 20210069170A1 · Stamets · 2021 [cited by applicant]
GB 2571696B · 2019 [cited by applicant]
WO 2015127556A1 · 2015 [cited by applicant]
WO 2018135943A1 · 2018 [cited by applicant]
WO 2022038299A1 · 2022 [cited by applicant]
Gukasyan et al., “Attenuation of Psilocybin Mushroom Effects During and After SSRI-SNRI Antidepressant Use”, Journal of Psychopharmacology, 00(0), 1-10, 2023. [cited by applicant]
Lane, et al., “Selective Serotonin Reuptake Inhibitor-Induced Serotonin Syndrome: Review”, Journal of Clinical Psychopharmacology, 17(3), 208-221, 1997. [cited by applicant]
Rafael G. dos Santos et al. “Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.” T… [cited by applicant]
International Search Report in International Application No. PCT/US2018/017710, dated Jul. 9, 2018. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/017710, dated Aug. 22, 2019. [cited by applicant]
Leung et al. ‘Baeocystin and norbaeocystin: New Analogs of psilocybin from Psilocybe baeocystis’, Journal of Pharmaceutical Sciences, Oct. 1968, vol. 57, pp. 1667-1671; p. 1667, p. 1668. [cited by applicant]
Daly et al. ‘The Chemorelease of Norepinephrine from Mouse Hearts. Structure-Activity Relationships. I. Sympathomimetic and Related Amines’, Journal of Medicinal Chemistry, May 1966, vol. 9, pp. 273-280; p. 273, p. 279. [cited by applicant]
Glennon ‘Central serotonin receptors as targets for drug research’, Journal of Medicinal Chemistry, Jan. 1987, vol. 30, pp. 1-12; p. 1, p. 6, p. 7. [cited by applicant]
Jensen et al. ‘Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic Mushroom [cited by applicant]
Pubmed Compound Summary for CID 17868117, ‘2-(4-Hydroxy-1H-indol-3-yl)ethyl-trimethylazanium’, U.S. National Library of Medicine, Dec. 4, 2007 (Dec. 4, 2007), p. 1-12 (https://pubchem.ncbi.nlm.nih.gov/compound/17868117)… [cited by applicant]
Niels Jensen , “Tryptamines as Ligands and Modulators of the Serotonin 5-HT 2A Receptor and the Isolation of Aeruginascin from the Hallucinogenic Mushroom [cited by applicant]
El-Aify et al., Pharmacal. Biochem. Behav., 2010, vol. 95, No. 4, pp. 434-442 (Year: 2010). [cited by applicant]
Vollenweider et al., Nature Reviews Neuroscience, 2010, vol. 11, No. 9, pp. 642-651 (Year: 201 0). [cited by applicant]
Maione et al., Br. J. Pharmacal., 2011, vol. 162, pp. 584-596 (Year: 2011). [cited by applicant]
Bigwood, J_ et al., “Variation of Psilocybin and Psilocin Levels with Repeated Flushes (Harvests) of Mature Sporocarps of Psilocybe Cubensis (Earle) Singer,” Journal of Ethnopharmacology, vol. 5 No. 3, pp. 287-291 (1982… [cited by applicant]
Li, I-Chen et al., “Neurohealth Properties of Hericium erinaceus Mycelia Enriched with Erinacines,” Behavioural Neurology, vol. 2018, pp. 1-11 (2018). [cited by applicant]
Chen et al., “Chemistry of Chinese Edible and Medicinal Fungi,” Shanghai Science and Technology Press, 2016, ISBN: 978-7-5439-6915-5. [cited by applicant]
Du Xiu-ju et al, Muchroom Toxins and Present Research of Its Utilization, Journal of Anhul Agri Sci, 2010,38 (13) : 7172-7174. [cited by applicant]
Wink (Medicines, 2015, vol. 2, pp. 251-286) (Year: 2015). [cited by applicant]
Russo (British Journal of Pharmacology, 2011, vol. 163, pp. 1344-1364) (Year: 2011). [cited by applicant]
Sanchez (“Bioactives from Mushroom and Their Application” (2017) in book Food Bioactives, M. Puri (ed), pp. 23-57) (Year: 2017). [cited by applicant]
Schuwald et al. PLoS One, 2013, vol. 8, No. 4, e59998, doi: 10.1371/journal.pone.0059998, 9 pages (Year: 2013). [cited by applicant]
Kasper et al. The World Journal of Biological Psychiatry, 2018, 19:6, pp. 412-420 (Published Online Jun. 19, 2017) (Year: 2018). [cited by applicant]
Nichols et al. “Psychedelics as Medicines: An Emerging New Paradigm”, Clinical Pharmacology & Therapeutics, Feb. 2017, vol. 101, No. 2, pp. 209-219 (Year: 2017). [cited by applicant]
Mahmood (“Bioactive Alkaloids from Fungi: Psilocybin”, Chapter 18 in book Natural Products, K.G. Ramawat, J.M. Merillon (eds.), 2013, pp. 523-552) (Year: 2013). [cited by applicant]
Thomas et al. Pharmacotherapy, 2015, vol. 35, No. 4, pp. 433-449 (Year: 2015). [cited by applicant]
Carhart-Harris et al. Lancet Psychiatry, 2016, vol. 3, pp. 619-627 (Year: 2016). [cited by applicant]
Zhuk et al., “Research on Acute Toxicity and the Behavioral Effects of Methanolic Extract from Psilocybin Mushrooms and Psilocin in Mice”, Toxins, 2015, pp. 1018-1029, 7(4). [cited by applicant]
Sard et al. “SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist”, . Bioorg Med Chem Lett., 2005, pp. 4555-4559, 15(20). [cited by applicant]
Ross et al., “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial”, Journal of Psychopharmacology, 2016… [cited by applicant]
Rambousek et al., “The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat”, Front. Behav. Neurosci., 2014, 8(180). [cited by applicant]
Tyls et al., “Psilocybin—summary of knowledge and new perspectives”, Eur Neuropsychopharmacol, 2014, pp. 342-356, 24(3). [cited by applicant]
Stebelska, “Fungal Hallucinogens Psilocin, Ibotenic Acid, and Muscimol: Analytical Methods and Biologic Activities”, Ther Drug Monit., 2013, pp. 420-442, 35(4). [cited by applicant]
Matsushima et al., “Historical overview of psychoactive mushrooms”, Inflammation and Regeneration, 2009, pp. 47-58, 29(1). [cited by applicant]
Alper (2008) “The ibogaine medical subculture” Journal of Ethnopharmacology. 115(1): 9-24. [cited by applicant]
“Amount of Niacin in Mushrooms” (http://www.dietandfitnesstoday.com/niacin-in-mushrooms.php; 12 pages) (Accessed Feb. 1, 2022)(Year: 2022). [cited by applicant]
Barrett (2006) “Patterns of simultaneous polysubstance use in drug using university students” Hum. Psychopharmacol. Clin. Exp. 21: 255-263, Apr. 6, 2006, Human Psychopharmacology Clinical and Experimental. [cited by applicant]
Becker et al., “Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects,” Clinical Pharmacology & Therapeutics, vol. … [cited by applicant]
Boys (2001) “Understanding reasons for drug use amongst young people a functional perspective” Health Education Research. 16(4):457-469. [cited by applicant]
Chadeayne et al., “Norpsilocin: freebase and fumarate salt,” Acta Crystallogr. E Crystallogr. Commun., Mar. 27, 2020;76(Pt 4) :589-593 (Year: 2020). [cited by applicant]
Chilton (1979) “Psilocin, Bufotenine and Serotonin: Historical and BiosyntheticObservations” Journal of Psychedelic Drugs. 11(1-2) pp. 61-69, Jan. 1979, Journal of Psychedelic Drugs. [cited by applicant]
Daniel, J., et al., ‘Clinical potential of psilocybin as a treatment for mental health conditions’, Mental Health Clinician, 2017, vol. 1, p. 24-28. [cited by applicant]
Dutton, Gail, Field Trip Health's New Psilocybin Research Facility Probes the Secrets of Shrooms, BioSpace, Pub. Feb. 26, 2021, https://www.biospace.com/article/field-trip-health-s-new-psilocybin-research-facility-probe… [cited by applicant]
Fozard (1978) “Dual mechanism of the stimulant action ofN, N-dimethyl-5-hydroxytryptamine (bufotenine) on cardiac sympathetic nerves” European Journal ofPharmacology. 49(1):25-30. [cited by applicant]
Gilman, “Compass Pathways Offers More Proof SSRI Drugs Do No Impede Psilocybin's Therapeutic Effect,” Psychedelic Spotlight, Dec. 13, 2021, https://psychedelicspotlight.com/compass-pathways-study-ssri-drugs-psilocybin-t… [cited by applicant]
Griffiths et al. “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blink trial.” Journal of Psychopharmacology, 30 (12), 201… [cited by applicant]
Hanes, K. R., ‘Serotonin, Psilocybin, and Body Dysmorphic Disorder: A Case Report’, Journal of Clinical Psychopharmacology, 1996, vol. 16(2), p. 188-189. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2018/061385, dated May 19, 2020. [cited by applicant]
International Search Report in International Application No. PCT/US2018/061385, dated Feb. 1, 2019. [cited by applicant]
Leeann, “Personal Story: Iboga and Psilocybin Mushrooms Saved Me on The Brink of Suicide” Mar. 16, 2015; retrieved from Web Archive, Resethttps://web.archive.org/web/20151203193 708/https://reset.me/personal-story/perso… [cited by applicant]
Lenz et al. “Identification of w-N-Methyl-4-hydroxytryptamine (Norpsilocin) as a Psilocybe Natural Product”, J. Nat. Prod., 2017, vol. 80, pp. 2835-2838 (Year: 2017). [cited by applicant]
Licht (2012) “Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases” Hum. Psychopharmacol. Clin. Exp. 27: 352-363. [cited by applicant]
Ma et al. “Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus,” Mycology, vol. 1, No. 2, 2010; pp. 92-98. [cited by applicant]
Ott (1999) “Human Pharmacology of Oral DMT Plus Harmine” Journal of Psychoactive Drugs.31(2):171-177. [cited by applicant]
PsyBio Therapeutics Corp., PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin, Mar. 23, 2021, https://www.newswire.ca/news-releases/psybio-therapeutics-initiates-process-developm… [cited by applicant]
Quednow, B. B, et al., ‘Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers’, Neuropsychopharmacology, 2012, vol. 37, p. 630-640. [cited by applicant]
Schechter (1998) “Candyflipping': Synergistic discriminative effect of LSD and MDMA” European Journal of Pharmacology. 314: 131-134. [cited by applicant]
Sessa (2015) “Underground MDMA-, LDS- and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary” Drug Science, Policy andLaw. 2(0):1-8. [cited by applicant]
Shelton (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance J. Clin. Psychiatry. 66(10): 1289-1297. [cited by applicant]
Sherwood et al. “Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaeocystin, Baeocystin, Norpsilocin, and Aeruginascin”, J. Nat. Prod., 2020, vol. 83, pp. 461-467 (Year: 2020). [cited by applicant]
Shroomery, “Re: LSA and Shrooms [Re: MycoKris]” 2006; retrieved from https://www.shroomery.org/forums/showflat.php/Number/60334 73#60334 73, retrieved Sep. 5, 2006. [cited by applicant]
Shulgin (1997) Tihkal: Tryptamines I Have Known and Loved: The Chemistry Continues, Chapter 48 line 256-261, 1997, Transform Press ISBN:0-9630096-9-9. [cited by applicant]
Szegedi (1996) “Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data” J. Clin. Psychiatry. 57(6):257-264. [cited by applicant]
Tittarelli (2015) “Recreational Use, Analysis and Toxicity of Tryptamines” Current Neuropharmacology. 13: 26-46. [cited by applicant]
White, “Mixing DXM and Other Drugs” 2015; retrieved from Web Archive, Erowid. https://web.archive.org/web/20150422070624/https://www .erowid.org/chemicals/dxm/faq/dxm_mixing.shtml, retrieved Apr. 22, 2015. [cited by applicant]
Bauer, “Scientists Synthesize and Test the Magic Mushroom Compounds Baeocystin, Norbaeocystin, Norpsilocin, and Aeruginascin,” Psychedelic Science Review, Mar. 5, 2020, https://psychedelicreview.com/scientists-synthesiz… [cited by applicant]
Dörner et al., “Genetic survey on Psilocybe natural products,” Wiley-VCH, pp. 1-8, 2022. [cited by applicant]
Health Canada, Notice to Stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP), Government of Canada, May 6, 2… [cited by applicant]
Stamets at al. Psilocybin Mushrooms of the World: An Identification Guide. First Edition. Berkeley, Calif: Ten Speed Press; 1996. [cited by applicant]
Ebersole et al., “Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy,” Molecular Pharmacology, 2003, vol. 63,… [cited by applicant]
Kawagishi et al., “Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycella of Hericium erinaceum,” Tetrahedron Letters, 1994, vol. 35, No. 10, pp. 1569-1572 (Year: 1994). [cited by applicant]
Carhart-Harris et al., “The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future,” Neuropsychopharmacology, 2017, vol. 42, pp. 2105-2113 (Published Online May 17, 2017) (Year: 2017). [cited by applicant]
Shirota et al., “Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of Magic Mushrooms”, J. Nat. Prod., 2003, vol. 66, pp. 885-887 (Year: 2003). [cited by applicant]
Yamada et al. (Chem. Pharm. Bull, 2002, vol. 50, No. 1, p. 92-99) (Year: 2002). [cited by applicant]